The European Medicines Agency (EMA) on Friday approved a new manufacturing site in France for the production of Moderna Inc's Covid-19 vaccine.
The site at Monts will be operated by Recipharm and produce the finished product, the EMA's committee for human medicines (CHMP) said.
Earlier this month, the CHMP approved two new sites in the United States to produce both active substance and the finished product for Moderna's vaccine.
It expects these moves to allow production of an additional one million to two million vials of ready-to-use vaccine for the European Union market every month.
Moderna already has a deal with Thermo Fisher Scientific's commercial manufacturing site in Greenville, North Carolina that will support production of "hundreds of millions" of doses.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Russia's Euro host imposes new restrictions as cases surge
UK joins US, EU, Canada in fresh sanctions on Belarus
Post-war Armenia votes in snap parliamentary polls
French far-right eyes gains in regional polls
Europe powers up electric car battery drive
Four killed, four badly injured in plane crash in Siberia
Covid Delta variant cases in UK increase
Thousands rally ahead of Armenia snap polls
Technology helps disabled harpist to play music ... with her eyes